Search hospitals > Missouri > Springfield
Clinvest Research LLC
Claim this profileSpringfield, Missouri 65807
Global Leader in Migraine
Global Leader in Vestibular Migraine
Conducts research for Headache
Conducts research for Type 2 Diabetes
Conducts research for Rheumatoid Arthritis
142 reported clinical trials
3 medical researchers
Summary
Clinvest Research LLC is a medical facility located in Springfield, Missouri. This center is recognized for care of Migraine, Vestibular Migraine, Headache, Type 2 Diabetes, Rheumatoid Arthritis and other specialties. Clinvest Research LLC is involved with conducting 142 clinical trials across 94 conditions. There are 3 research doctors associated with this hospital, such as David Gregory True, David True, MD, and Ralph Joseph Duda.Top PIs
David Gregory TrueClinvest Research LLC3 years of reported clinical research
Studies Obesity
Studies Type 2 Diabetes
22 reported clinical trials
25 drugs studied
David True, MDClinvest Research LLC5 years of reported clinical research
Studies Migraine
Studies Vestibular Migraine
16 reported clinical trials
20 drugs studied
Ralph Joseph DudaClinvest Research LLC3 years of reported clinical research
Studies Type 2 Diabetes
Studies Diabetes Mellitus
4 reported clinical trials
4 drugs studied
Clinical Trials running at Clinvest Research LLC
Migraine
Vestibular Migraine
Cardiovascular Disease
Psoriatic Arthritis
Atherosclerosis
Osteoarthritis
Hyperacusis
Photophobia
Nausea and Vomiting
Adolescent Health
Lasmiditan
for Pediatric Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Recruiting2 awards Phase 3
Rimegepant
for Pediatric Migraine
This trial aims to test the safety of rimegepant, a medication for treating migraines. The study focuses on children and adolescents aged 6 to 17 years who experience moderate to severe migraines. Rimegepant works by blocking a protein that triggers migraine pain, helping to alleviate symptoms.
Recruiting2 awards Phase 38 criteria
Ubrogepant
for Migraine
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting1 award Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Clinvest Research LLC?
Clinvest Research LLC is a medical facility located in Springfield, Missouri. This center is recognized for care of Migraine, Vestibular Migraine, Headache, Type 2 Diabetes, Rheumatoid Arthritis and other specialties. Clinvest Research LLC is involved with conducting 142 clinical trials across 94 conditions. There are 3 research doctors associated with this hospital, such as David Gregory True, David True, MD, and Ralph Joseph Duda.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.